Current and Future Treatment Options for Cerebral Cavernous Malformations

Area of Science:

• Neuroscience
• Vascular Biology
• Pharmacology

Background:

• Cerebral cavernous malformations (CCMs) are vascular lesions causing seizures, hemorrhage, and neurological deficits.
• CCMs can be familial (multifocal) or sporadic (single lesion), with current treatments including surgery and radiation, which have risks, especially in eloquent brain areas.
• Asymptomatic lesions are generally not treated, highlighting the need for alternative therapeutic strategies.

Purpose of the Study:

• To review current treatments for CCMs.
• To explore potential pharmacologic treatments targeting aberrant molecular signaling pathways in CCMs.
• To discuss emerging therapies and ongoing clinical trials.

Main Methods:

• A narrative review of literature identified through PubMed searches on CCM treatments.
• Analysis of molecular signaling pathways implicated in CCM pathogenesis, particularly RhoA/Rho-associated kinase.
• Review of preclinical and clinical trial data for pharmacologic agents.

Main Results:

• Overactivation of RhoA/Rho-associated kinase in endothelial cells contributes to CCM development.
• Inhibition of RhoA/Rho-associated kinase (e.g., with fasudil, statins, NRL-1049) reduced lesion burden in mouse models.
• Clinical trials are evaluating atorvastatin, NRL-1049, propranolol, and REC-994 for CCM treatment efficacy and safety.

Conclusions:

• Pharmacologic inhibition of RhoA/Rho-associated kinase is a promising therapeutic strategy for CCMs.
• Agents like propranolol and REC-994 also show potential in preclinical and early clinical studies.
• Further clinical evaluation is crucial for developing effective pharmacologic treatments for CCM patients.